The CBD-Intel Cosmetics hub covers all topicals, balms and related CBD products.
This short regulatory report provides an overview of the current GMP regulations for cosmetics being place on the market in the EU
Despite a lack of strong evidence for the effectiveness of cannabinoids in dealing with skin issues, more and more UK brands have launched “cannabeauty” ranges, which incorporate skin care, body care and cosmetics
Market limitations in Europe due to EU novel food regulations mean members of the CBD industry are likely to look at areas such as cosmetics and products for animals, according to a number of experts in the field
The regulatory landscape for CBD products varies across the world and constantly changing, making compliance a potential minefield. This report provides an overview of the current legal status of CBD cosmetics in key markets around the world
The launch of many CBD-containing foods, beverages and cosmetics in California has been delayed further as a bill legalising their sale is now not expected to pass before the end of the legislative session, which ends on on 13th September
CBD’s entry in the European Commission’s database of cosmetics ingredients has been expanded to differentiate it from generic cannabis and by-products. The move offers more, but not total, clarity
According to EU authorities, CBD and other cannabis extracts could be deemed illegal as an ingredient in cosmetics. However, individual member states have not made the same interpretation of the rules
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.
Free sample available
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
